- "We believe market growth (for Erivedge) will continue in 2014, providing a revenue stream and increasing visibility for Curis (CRIS -4.2%)," says analyst Joe Pantginis. He notes Erivedge revenue has grown continuously since its 2012 launch, with Roche reporting $28M in Q4 sales. Curis, of course, receives royalty payments on those sales.
- Adding to that, says Pantginis, is increased clarity on Curis' internal pipeline.
- Earnings coverage last Thursday
at Zacks.com (Fri, 8:51AM)